-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $40

Benzinga·04/24/2026 14:15:09
Listen to the news
RBC Capital analyst Brian Abrahams initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Outperform rating and announces Price Target of $40.